Allarity Therapeutics, Inc. (ALLR)
| Previous Close | 0.5793 |
| Open | 0.5751 |
| Bid | 0.4480 x 200 |
| Ask | 0.6205 x 2200 |
| Day's Range | 0.5500 - 0.6470 |
| 52 Week Range | 0.5500 - 283.2000 |
| Volume | |
| Avg. Volume | 3,486,112 |
| Market Cap | 10.742M |
| Beta (5Y Monthly) | 0.52 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Allarity Therapeutics Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement
Boston (May 20, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced that it has received formal written notice from The Nasdaq Stock Market, LLC’s Office of General Counsel (“Nasdaq”) that the Company has regained compliance with the minimum stockholders' equity requirement as set forth in Nasdaq Listing Rule 5550(b)(1) (the “Equity Rule”). This conf
- GlobeNewswire
Allarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinical Benefits from Phase 2 Trial, NASDAQ Compliance, and Significant Improvement in Cash and Equity Balances
- Phase 2 Trial of Stenoparib Concluded Early due to Clear Clinical Benefits Achieved - On Track to Regain Compliance with All Nasdaq Listing Requirements - No Variable Priced Securities are Outstanding - Warrant Overhang Near Elimination - Allarity Withdraws its Form S-1 - Establishes Equity of $15 Million - Cash Balance of $14 Million Boston (May 14, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to deve
- GlobeNewswire
Allarity Therapeutics Announces that All Series A Preferred and All Variable Priced Warrants have Converted to Common Stock
- Conversions Eliminate All Variable Priced Derivative Securities - Conversions Eliminate Any Market Overhang from Warrants - Series A Preferred and Warrant Conversions were Investor Initiated - Limited Number of Warrants Convertible at $20 Per Share Remain - Company Has Paid Off All Bridge Notes in Full Boston (May 7, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, tod
